(SeaPRwire) –   PALO ALTO, Calif., May 28, 2026 — Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial biotechnology company specializing in retinal therapies and dedicated to the research, development, and commercialization of transformative treatments, announced today that its Chief Executive Officer, Victor Perlroth, M.D., is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation will take place on Thursday, June 4, 2026, at 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time).

The presentation will be webcast live and can be accessed via the “Events and Presentations” page on Kodiak’s investor relations website at http://ir.kodiak.com/. A replay of the webcast will be available for a limited period after the conference.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a precommercial biotechnology company focused on the retina, committed to discovering, developing, and bringing to market groundbreaking therapeutics. The company’s mission is to apply novel scientific approaches to the design and production of next-generation retinal medicines aimed at preventing and treating the world’s primary causes of blindness. Kodiak’s pipeline includes three late-stage clinical programs: Zenkuda (tarcocimab tedromer), KSI-501, and KSI-101.

Further information is available at www.kodiak.com.

Kodiak^®, Kodiak Sciences^®, ABC^®, ABC Platform^®, ABCD, and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various jurisdictions worldwide.

SOURCE Kodiak Sciences Inc.